

Comparative phase I randomized open-label pilot clinical trial of Gynophilus® (Lcr regenerans®) Immediate Release capsules versus Slow Release muco-adhesive tablets.

European Journal of Clinical Microbiology & Infectious Diseases

Caroline DAUSSET^{a#}, Stéphane PATRIER^a, Paweł GAJER^b, Claudia THORAL^a, Yann LENGLLET^c, Jean-Michel CARDOT^d, Philippe JUDLIN^e, Jacques RAVEL^b, Adrien NIVOLIEZ^a

^a Research and development department, BIOSE, Aurillac, France

^b Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland, USA

^c Gynecology and obstetrics department, Jacques Lacan Hospital Center, Vichy, France


^d Biopharmaceutical Department, UMR MEDIS, Faculty of Pharmacy, University of Clermont Auvergne, Clermont-Ferrand, France

^e Gynecology and Obstetrics Department, Nancy University Hospital, Nancy, France


Corresponding author, c.dausset@biose.com

Online Resource 3: Representative longitudinal vaginal microbiota profiles of women enrolled in each of the treatment arms ((a) treatment 1; (b) treatment 2; (c) treatment 3; (d) reference treatment). *Lactobacillus casei* (pink) indicates the live biotherapeutic microorganism Lcr35®. Vertically, each column represents one sampling day. Horizontally, community state type (CST) distribution for all samples collected by women was determined by the abundance of phylotype composition represented in the taxa relative abundance histogram. CST reflect the dominant microorganisms, CST-I is dominated by *L. crispatus*, CST-II by *L. gasseri*, CST-III by *L. iners*, CST-V by *L. jensenii*, CST-VI by *L. casei* (*Lcr35*®) and CST-IV is characterized by a diverse set of strict and facultative anaerobes.


Subject 001-001 REF (1 caps/day)




Subject 001–003 TRT2 (1 tab/4 days)




Subject 001-004 TRT1 (1 tab/3 days)




Subject 001–005 REF (1 caps/day)




Subject 001-006 TRT3 (1 tab/5 days)




Subject 001-007 TRT2 (1 tab/4 days)




Subject 001-008 TRT1 (1 tab/3 days)




Subject 001-009 REF (1 caps/day)




Subject 001-010 TRT2 (1 tab/4 days)




Subject 001-011 TRT3 (1 tab/5 days)



Subject 001-012 TRT1 (1 tab/3 days)




Subject 001-013 TRT1 (1 tab/3 days)




Subject 001-014 REF (1 caps/day)


CSTs




Subject 001–015 TRT3 (1 tab/5 days)




Subject 001-016 TRT2 (1 tab/4 days)




Subject 001–017 TRT1 (1 tab/3 days)



Subject 001–018 TRT3 (1 tab/5 days)




Subject 001-019 TRT2 (1 tab/4 days)




Subject 001–020 REF (1 caps/day)


CSTs




Subject 001-021 TRT 3 (1 tab/5 days)




Subject 001–022 REF (1 caps/day)




Subject 001–023 TRT2 (1 tab/4 days)




Subject 002-001 REF (1 caps/day)




Subject 002-002 TRT2 (1 tab/4 days)




Subject 002-003 TRT1 (1 tab/3 days)




Subject 002–004 TRT3 (1 tab/5 days)




Subject 002-005 TRT1 (1 tab/3 days)




Subject 002–006 REF (1 caps/day)




Subject 002-007 TRT3 (1 tab/5 days)




Subject 002-008 TRT2 (1 tab/4 days)



Subject 002-009 REF (1 caps/day)



Subject 002-011 TRT1 (1 tab/3 days)



Subject 002-012 TRT2 (1 tab/4 days)

